The lipid and non-lipid effects of statins

Pharmacology and Therapeutics

Volumn 99, Issue 1, 2003, Pages 95-112

  Wierzbicki, Anthony S ^a   Poston, Robin ^a   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

3 hydroxy 3 methyl glutaryl coenzyme A reductase; Cardiovascular system; Inflammation; Lipids; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESTYRAMINE; CYCLOSPORIN; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BIOACCUMULATION; BIOCHEMISTRY; BLOATING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DIARRHEA; DISEASE COURSE; DRUG METABOLISM; GASTROINTESTINAL DISEASE; HEART TRANSPLANTATION; HUMAN; HYPOTHYROIDISM; MEDICAL RESEARCH; MUSCLE CELL; MYALGIA; MYOSITIS; NAUSEA; NEUROPATHY; PATHOGENESIS; PRIORITY JOURNAL; REDUCTION; REGRESSION ANALYSIS; RISK FACTOR; STROKE; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0038201555     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00055-X     Document Type: Article

References (159)

1. Aboushadi N., Engfelt W.H., Paton V.G., Krisans S.K. Role of peroxisomes in isoprenoid biosynthesis. J Histochem Cytochem. 47:1999;1127-1132.
2. Alfon J., Royo T., Garcia-Moll X., Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol. 19:1999;1812-1817.
3. Athyros V.G., Papageorgiou A.A., Mercouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis E.O., Demitriadis D.S., Kontopoulos A.G. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus usual care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 18:2002;220-228.
4. Bae S.H., Lee J.N., Fitzky B.U., Seong J., Paik Y.K. Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome-related protein. J Biol Chem. 274:1999;14624-14631.
5. Bjerre L.M., LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 110:2001;716-723.
6. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., Rupprecht H.J. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 106:2002;24-30.
7. Borghi C., Prandin M.G., Costa F.V., Bacchelli S., Degli Esposti D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 35:2000;549-555.
8. Breitling R., Krisans S.K. A second gene for peroxisomal HMG-CoA reductase? A genomic reassessment. J Lipid Res. 43:2002;2031-2036.
9. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
10. Bustos C., Hernandez-Presa M.A., Ortego M., Tunon J., Ortega L., Perez F., Diaz C., Hernandez G., Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 32:1998;2057-2064.
11. Byington R.P., Jukema J.W., Salonen J.T., Pitt B., Bruschke A.V., Hoen H., Furberg C.D., Mancini G.B. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 92:1995;2419-2425.
12. Byington R.P., Davis B.R., Plehn J.F., White H.D., Baker J., Cobbe S.M., Shepherd J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 103:2001;387-392.
13. Camera M., Toschi V., Comparato C., Baetta R., Rossi F., Fuortes M., Ezekowitz M.D., Paoletti R., Tremoli E. Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost. 87:2002;748-755.
14. Capodici C., Pillinger M.H., Han G., Philips M.R., Weissmann G. Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/MEK/Erk via a 5-lipoxygenase-dependent pathway. J Clin Invest. 102:1998;165-175.
15. Cardozo C., Wu X., Pan M., Wang H., Fisher E.A. The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein B-100. Biochemistry. 41:2002;10105-10114.
16. Chan L., Chang B.H., Liao W., Oka K., Lau P.P. Apolipoprotein B: from editosome to proteasome. Recent Prog Horm Res. 55:2000;93-125.
17. Chan A.W., Bhatt D.L., Chew D.P., Quinn M.J., Moliterno D.J., Topol E.J., Ellis S.G. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 105:2002;691-696.
18. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., Falco A., Cuccurullo F., Davi G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 106:2002;399-402.
19. Cohen L.H., Pieterman E., van Leeuwen R.E., Overhand M., Burm B.E., van der Marel G.A., van Boom J.H. Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol. 60:2000;1061-1068.
20. Comparato C., Altana C., Bellosta S., Baetta R., Paoletti R., Corsini A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis. 11:2001;328-343.
21. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933.
22. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 69:1993;377-381.
23. Davis R.A. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1440:1999;1-31.
24. Degraeve F., Bolla M., Blaie S., Creminon C., Quere I., Boquet P., Levy-Toledano S., Bertoglio J., Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem. 276:2001;46849-46855.
25. de Groot E., Jukema J.W., Montauban van Swijndregt A.D., Zwinderman A.H., Ackerstaff R.G., van der Steen A.F., Bom N., Lie K.I., Bruschke A.V. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study. J Am Coll Cardiol. 31:1998;1561-1567.
26. Desager J.P., Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 31:1996;348-371.
27. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622.
28. Dujovne C.A., Moriarty P.M. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia. Clin Ther. 18:1996;392-410.
29. Edwards C.J. Statins and bone morphogenetic proteins: new pathways in bone formation. Ann Acad Med Singap. 31:2002;245-247.
30. Ekins S., Mirny L., Schuetz E.G. A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm Res. 19:2002;1788-1800.
31. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 95:1998;8880-8885.
32. Engström G., Lind P., Hedblad B., Stavenow L., Janzon L., Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 105:2002;2632-2637.
33. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res. 83:1998;683-690.
34. Eto M., Kozai T., Cosentino F., Joch H., Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 105:2002;1756-1759.
35. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 285:2001;2486-2497.
36. Farmer J.A. Pleiotropic effects of statins. Curr Atheroscler Rep. 2:2000;208-217.
37. Flinn H.M., Ridley A.J. Rho stimulates tyrosine phosphorylation of focal adhesion kinase, p130 and paxillin. J Cell Sci. 109:1996;1133-1141.
38. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
39. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
40. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
41. Heeschen C., Hamm C.W., Laufs U., Snapinn S., Bohm M., White H.D. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 105:2002;1446-1452.
42. Herd J.A. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am J Med. 104:1998;42S-49S.
43. Higgins J.B., Casey P.J. The role of prenylation in G protein assembly and function. Cell Signal. 8:1996;433-437.
44. Hogenboom S., Romeijn G.J., Houten S.M., Baes M., Wanders R.J., Waterham H.R. Absence of functional peroxisomes does not lead to deficiency of enzymes involved in cholesterol biosynthesis. J Lipid Res. 43:2002;90-98.
45. Hussein O., Rosenblat M., Schlezinger S., Keidar S., Aviram M. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to platelets. Br J Clin Pharmacol. 44:1997;77-84.
46. Igel M., Sudhop T., von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 57:2001;357-364.
47. Ikeda U., Shimada K. Statins and monocytes. Lancet. 353:1999;2070.
48. Illingworth D.R., Crouse J.R. III, Hunninghake D.B., Davidson M.H., Escobar I.D., Stalenhoef A.F., Paragh G., Ma P.T., Liu M., Melino M.R., O'Grady L., Mercuri M., Mitchel Y.B. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 17:2001;43-50.
49. Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S., Nakajima T., Hokari S., Komoda T., Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 67:2000;863-876.
50. Ishibashi T., Nagata K., Ohkawara H., Sakamoto T., Yokoyama K., Shindo J., Sugimoto K., Sakurada S., Takuwa Y., Teramoto T., Maruyama Y. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta. 1590:2002;123-130.
51. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 292:2001;1160-1164.
52. Istvan E.S., Palnitkar M., Buchanan S.K., Deisenhofer J. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J. 19:2000;819-830.
53. Jeppesen U., Gaist D., Smith T., Sindrup S.H. Statins and peripheral neuropathy. Eur J Clin Pharmacol. 54:1999;835-838.
54. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 19:1999;1051-1059.
55. Jira P.E., Wevers R.A., de Jong J., Rubio-Gozalbo E., Janssen-Zijlstra F.S., van Heyst A.F., Sengers R.C., Smeitink J.A. Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res. 41:2000;1339-1346.
56. Joint British Recommendations on Prevention of Coronary Heart Disease in Clinical Practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association Heart. 80(Suppl. 2):1998;S1-S29.
57. Jones S.P., Trocha S.D., Lefer D.J. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol. 21:2001;2059-2064.
58. Kawakami A., Tanaka A., Nakajima K., Shimokado K., Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 91:2002;263-271.
59. Kluft C., de Maat M.P., Gevers Leuven J.A., Potter van Loon B.J., Mohrschladt M.F. Statins and C-reactive protein. Lancet. 353:1999;1274.
60. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A., Trosian K., Hamilton M.A., Moriguchi J.D., Kawata N., Hage A., Drinkwater D.C., Stevenson L.W. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
61. Kothe H., Dalhoff K., Rupp J., Muller A., Kreuzer J., Maass M., Katus H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 101:2000;1760-1763.
62. Kovacs W.J., Olivier L.M., Krisans S.K. Central role of peroxisomes in isoprenoid biosynthesis. Prog Lipid Res. 41:2002;369-391.
63. Krisans S.K. Cell compartmentalization of cholesterol biosynthesis. Ann NY Acad Sci. 804:1996;142-164.
64. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V., Lie K.I., Kastelein J.J. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 338:1998;86-93.
65. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 6:2000;1004-1010.
66. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 273:1998;24266-24271.
67. Laufs U., Fata V.L., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:1997;31725-31729.
68. Laufs U., Gertz K., Huang P., Nickenig G., Bohm M., Dirnagl U., Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 31:2000;2442-2449.
69. Lefer D.J. Statins as potent antiinflammatory drugs. Circulation. 106:2002;2041-2042.
70. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
71. Leibovitz E., Hazanov N., Zimlichman R., Shargorodsky M., Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens. 14:2001;1096-1098.
72. Leitinger B., Hogg N. The involvement of lipid rafts in the regulation of integrin function. J Cell Sci. 115:2002;963-972.
73. Liao F., Andalibi A., Qiao J.H., Allayee H., Fogelman A.M., Lusis A.J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest. 94:1994;877-884.
74. Liu L., Moesner P., Kovach N.L., Bailey R., Hamilton A.D., Sebti S.M., Harlan J.M. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem. 274:1999;33334-33340.
75. Lum A.F., Green C.E., Lee G.R., Staunton D.E., Simon S.I. Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J Biol Chem. 277:2002;20660-20670.
76. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPAR-alpha and induces HDL apoA-I. J Clin Invest. 107:2001;1423-1432.
77. Matar P., Rozados V.R., Binda M.M., Roggero E.A., Bonfil R.D., Scharovsky O.G. Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis. 17:1999;19-25.
78. Mehta J.L., Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol. 39:2002;1429-1435.
79. MRC/BHF Heart Protection Study Cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J. 20:1999;725-741.
80. MRC/BHF Heart Protection Study Cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
81. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology. 59:2002;990-997.
82. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 100:1999;2131-2134.
83. Niwa S., Totsuka T., Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol. 18:1996;669-675.
84. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
85. Opper C., Clement C., Schwarz H., Krappe J., Steinmetz A., Schneider J., Wesemann W. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis. 113:1995;211-217.
86. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 100:1997;2671-2679.
87. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 21:2001;3-5.
88. Poston R.N., Johnson-Tidey R.R. Localized adhesion of monocytes to human atherosclerotic plaques demonstrated in vitro: implications for atherogenesis. Am J Pathol. 149:1996;73-80.
89. Prasad G.V., Ahmed A., Nash M.M., Zaltzman J.S. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int. 63:2003;360-364.
90. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 19:1999;2894-2900.
91. Pruefer D., Makowski J., Schnell M., Buerke U., Dahm M., Oelert H., Sibelius U., Grandel U., Grimminger F., Seeger W., Meyer J., Darius H., Buerke M. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 106:2002;2104-2110.
92. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., Baillie T.A. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 30:2002;505-512.
93. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 30:2002;1280-1287.
94. Puccetti L., Bruni F., Bova G., Cercignani M., Palazzuoli A., Console E., Auteri A., Pasqui A.L. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 11:2001;378-387.
95. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818.
96. Ridker P.M. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation. 105:2002;2583-2585.
97. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235.
98. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
99. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 101:2000;2149-2153.
100. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 285:2001;2481-2485.
101. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
102. Ridley A.J., Hall A. Signal transduction pathways regulating Rho-mediated stress fibre formation: requirement for a tyrosine kinase. EMBO J. 13:1994;2600-2610.
103. Romano M., Diomede L., Sironi M., Massimiliano L., Sottocorno M., Polentarutti N., Guglielmotti A., Albani D., Bruno A., Fruscella P., Salmona M., Vecchi A., Pinza M., Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 80:2000;1095-1100.
104. Romano M., Mezzetti A., Marulli C., Ciabattoni G., Febo F., Di Ienno S., Roccaforte S., Vigneri S., Nubile G., Milani M., Davi G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med. 48:2000;183-189.
105. Rosenson R.S., Brown A.S. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr Opin Lipidol. 13:2002;625-630.
106. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. JAMA. 279:1998;1643-1650.
107. Ross S.D., Allen I.E., Connelly J.E., Korenblat B.M., Smith M.E., Bishop D., Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 159:1999;1793-1802.
108. Rost N.S., Wolf P.A., Kase C.S., Kelly-Hayes M., Silbershatz H., Massaro J.M., D'Agostino R.B., Franzblau C., Wilson P.W. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 32:2001;2575-2579.
109. Rusnak N., Krisans S.K. Diurnal variation of HMG-CoA reductase activity in rat liver peroxisomes. Biochem Biophys Res Commun. 148:1987;890-895.
110. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
111. Sacks F.M., Tonkin A.M., Craven T., Pfeffer M.A., Shepherd J., Keech A., Furberg C.D., Braunwald E. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 105:2002;1424-1428.
112. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718.
113. Serrano C.V. Jr., Yoshida V.M., Venturinelli M.L., D'Amico E., Monteiro H.P., Ramires J.A.F., da Luz P.L. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis. 157:2001;505-512.
114. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 287:2002;3215-3222.
115. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
116. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360:2002;1623-1630.
117. Sparrow C.P., Burton C.A., Hernandez M., Mundt S., Hassing H., Patel S., Rosa R., Hermanowski-Vosatka A., Wang P.R., Zhang D., Peterson L., Detmers P.A., Chao Y.S., Wright S.D. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 21:2001;115-121.
118. Sposito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). J Am Coll Cardiol. 83:1999;1497-1499.
119. Stalker T.J., Lefer A.M., Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 133:2001;406-412.
120. Stanislaus R., Gilg A.G., Singh A.K., Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett. 333:2002;167-170.
121. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
122. Sukhova G.K., Williams J.K., Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 22:2002;1452-1458.
123. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 21:2001;1712-1719.
124. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060.
125. Terkeltaub R., Solan J., Barry M. Jr., Santoro D., Bokoch G.M. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol. 55:1994;749-755.
126. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
127. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
128. The Scandinavian Simvastatin Survival Study (4S) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 344:1994;1383-1389.
129. Thompson P.D., Moyna N.M., White C.M., Weber K.M., Giri S., Waters D.D. The effects of hydroxyl-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis. 161:2002;301-306.
130. Tokui T., Nakai D., Nakagomi R., Yawo H., Abe T., Sugiyama Y. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res. 16:1999;904-908.
131. Tonkin A.M., Colquhoun D., Emberson J., Hague W., Keech A., Lane G., MacMahon S., Shaw J., Simes R.J., Thompson P.L., White H.D., Hunt D. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet. 356:2000;1871-1875.
132. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
133. Tu H., Okamoto A.Y., Shan B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc Med. 10:2000;30-35.
134. Undas A., Brummel K.E., Musial J., Mann K.G., Szceklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing Va production. Circulation. 103:2001;2248-2253.
135. van Kooyk Y., Figdor C.G. Avidity regulation of integrins: the driving force in leukocyte adhesion. Curr Opin Cell Biol. 12:2000;542-547.
136. Vaughan C.J., Gotto A.M. Jr., Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 35:2000;1-10.
137. Velussi M., Cernigoi A.M., Tortul C., Merni M. Atorvastatin for the management of type-2 diabetic patients with dyslipidemia. A mid-term (9 month) treatment experience. Diabetes Nutr Metab. 12:1999;407-412.
138. Walters C.E., Pryce G., Hankey D.J., Sebti S.M., Hamilton A.D., Baker D., Greenwood J., Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol. 168:2002;4087-4094.
139. Wanders R.J., Tager J.M. Lipid metabolism in peroxisomes in relation to human disease. Mol Aspects Med. 19:1998;69-154.
140. Wang E., Casciano C.N., Clement R.P., Johnson W.W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 18:2001;800-806.
141. Weber C., Erl W., Weber K.S., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 30:1997;1212-1217.
142. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Coltens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:2001;687-692.
143. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
144. Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., Chu C.H., George R.J., Gordon D.A., Jamil H., Jolibois K.G., Kunselman L.K., Lan S.J., Maccagnan T.J., Ricci B., Yan M., Young D., Chen Y., Fryszman O.M., Logan J.V., Musial C.L., Poss M.A., Robl J.A., Simpkins L.M., Slusarchyk W.A., Sulsky R., Taunk P., Magnin D.R., Tino J.A., Lawrence R.M., Dickson J.K. Jr., Biller S.A. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 282:1998;751-754.
145. Wierzbicki A.S. Statins: myalgia and myositis. Br J Cardiol. 9:2002;193-194.
146. Wierzbicki A.S., Mikhailidis D.P. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol. 84:2002;53-57.
147. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvastatin on plasma fibrinogen. Lancet. 351:1998;591-592.
148. Wierzbicki A.S., Lumb P.J., Chik G., Crook M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 53:1999;609-611.
149. Wierzbicki A.S., Lumb P.J., Chik G., Crook M.A. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol. 86:2000;547-549.
150. Wierzbicki A.S., Lumb P.J., Chik G. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 55:2001;673-675.
151. Wierzbicki A.S., Mikhaildis D.P., Wray R., Schachter M., Cramb R., Simpson W.B., Byrne C.D. Statin and fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin. 2003;. (in press).
152. Wierzbicki A.S., Mikhailidis D.P., Reynolds T.M. More on PROSPER. Lancet. 361:2003;1135-1136.
153. Wojciak-Stothard B., Williams L., Ridley A.J. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 145:1999;1293-1307.
154. Wood D., de Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis. 140:1998;199-270.
155. Woollard K.J., Phillips D.C., Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol. 130:2002;256-262.
156. Yoshida M., Sawada T., Ishii H., Gerszten R.E., Rosenzweig A., Gimbrone M.A. Jr., Yasukochi Y., Numano F. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 21:2001;1165-1171.
157. Zambon A., Deeb S.S., Brown B.G., Hokanson J.E., Brunzell J.D. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 103:2001;792-798.
158. Zamvil S.S., Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology. 59:2002;970-971.
159. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 65:1996;241-269.